1 completed, 1 recruiting, 1 terminated, 1 withdrawn. 2 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 1, Withdrawn 1 |
| Not applicable | 1 | Completed 1 |
Follow Pharmascience Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of COVID-19 Isoquercetin (IQC-950AN) - COVID-19 | Phase 2 | Withdrawn | Institut de Recherches Cliniques de Montreal | 2022-01-01 | 2025-03-24 | |
| Efficacy, Safety and Tolerability of Enteric-Coated Cholestyramine Capsules for Adult Short Bowel Syndrome Enteric-Coated Cholestyramine (ECC) Capsule, Placebo - Short Bowel Syndrome | Phase 2 | Terminated | Pharmascience Inc. | 13 | 2019-10-15 | 2022-07-19 |
| Early Effect of Cingal® Compared to Monovisc® in Patients With Osteoarthritis of the Knee Cingal® (Hyaluronic Acid plus Triamcinolone Hexacetonide), Monovisc® (Sodium hyaluronate) - Osteoarthritis, Knee | Not applicable | Completed | Pharmascience Inc. | 60 | 2017-04-05 | 2020-04-21 |
| Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People. HIV Infections, Hepatitis B | Recruiting | Syneos Health | 24258 | 1989-01-01 | 2025-04-01 |
COVID-19 (1) · HIV Infections (1) · Hepatitis (1) · Hepatitis B (1) · Osteoarthritis, Knee (1) · Short Bowel Syndrome (1)
Capsules (1) · isoquercitrin (1)
Canada (1) · Poland (1) · United States (1)
Jessica D Albano, PhD, MPH (1) · Kinga Szczepanek, MD (1) · Konrad Matysiak, MD, PhD (1) · Marek Kunecki, MD, PhD (1) · Mohit Bhandari, MD, PhD (1)
2018 (1)